- Open Access
Tegumental alterations and resistance of Fasciola gigantica adult worms exposed to flukicides in Egypt
Beni-Suef University Journal of Basic and Applied Sciences volume 11, Article number: 106 (2022)
The current study was designed to investigate the in vitro effect of commercially available fasciolicides; albendazole (40 and 400 µg/ml), triclabendazole, rafoxanide and nitroxynil (50 and 100 µg/ml, each) against Fasciola gigantica adult worms. For all, worms were incubated for 3 h. Worm's motility was macroscopically and microscopically detected. Reduction of egg deposition was estimated. Alterations of worm's cuticle post-treatments were recorded using scanning electron microscopy (SEM).
Nitroxynil had the most flukicidal effect with mild movement quickly disappeared within 15 min post-treatment. It showed the highest egg reduction (88.3% and 95% at concentrations of 50 and 100 µg/ml, respectively). Findings of SEM showed severe furrowing and destruction of spines. In rafoxanide-treated group, the motility disappeared 75 min post-treatment, and the egg deposition was significantly (P ≤ 0.05) reduced to 70% and 85% at the same concentrations. Teguments showed thickening, moderate furrowing and destruction of the spines. Albendazole showed the lowest effect: the motility of the worms was observed till 160 min post-treatment and the egg reduction was 43% and 75% at the same concentrations. Interestingly, in albendazole-treated flukes, the tegument had severe furrowing and spines were completely sloughed. Similarly, in triclabendazole-treated flukes, worms motility was observed till 160 min post-treatment and the egg reduction was 76.6% and 88.3%. The tegument showed swelling and mild furrowing with moderately damaged spines.
Nitroxynil was the most potent flukicide inducing evidential cuticular changes. Although albendazole induced the most potent cuticular damage, it showed the lowest flukicidal effect. Further in vivo study to investigate resistance/susceptibility of Fasciola species in cattle and buffaloes will be carried out.
Fascioliasis is a disease of particular concern causing severe economic losses for sheep and cattle production worldwide. It has an estimated annual economic losses approximately $ 2–3 billion worldwide [1, 2] and US $ 29.2 million in Egypt . It causes economic losses comprising reduced fertility and productivity and livers condemnation [4, 5]. Both fasciolids, Fasciola hepatica and F. gigantica, are common in Egypt . In Egypt, the prevalence of fascioliasis was 50.6% and 32.3% in cattle and buffaloes, respectively . Moreover, Fasciola species has zoonotic importance; about 830,000 human infections were recorded in Egypt .
Chemotherapy is the practical method that is effective against fascioliasis among infected animals and humans worldwide. Benzimidazoles (BZ) are the most common anthelmintics that are being used in both veterinary and human medication . The primary mode of action implies their interaction with the tubulin and secretory processes of the worms . Albendazole (ABZ) is the broadest spectrum member of the benzimidazole group. It acts against nematodes, cestodes and trematodes [11,12,13]. Triclabendazole (TCBZ) is a benzimidazole derivative that is being massively used against fascioliasis in humans and animals [14, 15]. Triclabendazole has a unique flukicidal activity against mature and immature flukes aging 2 weeks or more . Rafoxanide is a flukicide belonging to salicylanilides, and causes depletion in glycogen, glucose-6-phosphate and ATP in mature flukes . Nitroxynil is one of halogenated phenol flukicides, highly active against adult liver flukes (aged 6–8 weeks), with no effect on the earlier stages [18, 19]. The rapid spastic paralysis and uncoupler of oxidative phosphorylation effects of nitroxynil were documented .
The massive use of those compounds results in the developing of the anthelmintic resistance [21, 22]. The first report of Fasciola species resistance against flukicides was documented in 1980 . Albendazole failed to treat fascioliasis in a sheep farm in the south-western Sweden . Triclabendazole resistance has been proved in Australia since 1995 . Screening activity of flukicides against Fasciola species can be conducted under laboratory and field conditions. In vitro egg hatching assay for screening susceptibility/resistance of Fasciola species has been carried out [26, 27]. Moreover, alterations in the tegument of Fasciola adult worms exposed to flukicides were recorded in previous literature. The tegument is one of the first tissues to be exposed to anthelmintics, a major pharmacological target. SEM has been proven to be a valuable method for assessing surface changes in flukes treated by anthelmintics. Disruption of the tegument caused by flukicides causes serious effects on flukes, as anthelmintics contact deep tissues and internal organs . The use of SEM to screen activity of flukicides against Fasciola species tegument was previously recorded [29, 30].
Therefore, the current study was designed to investigate the in vitro susceptibility and tegument alterations of Fasciola gigantica adult worms exposed to high concentrations of commercially used flukicides using SEM in Egypt.
2.1 Sampling and collection of the worms
Adult flukes were collected from a liver of male buffalo aged 2 years, from Beni-Suef (Coordinates: 29°04′ N 31°05′ E) municipal abattoir, Egypt. The infected liver was transported to the department of Parasitology, Faculty of Veterinary Medicine, Beni-Suef University, Egypt, in an ice box within 1 h post slaughtering. All flukes washed several times with saline and then transferred to Petri dishes containing saline. The collected flukes were identified based on their morphological features according to Ashrafi et al. . Also, the collected worms were molecularly identified (Unpublished data). Motility and activity of the adult flukes were assessed before the treatment.
2.2 Screening activity of the used flukicides
Commercially available flukicides: Albendazole® 10%, Pharma Swede, Egypt; Triclabendazole (Triclafluke 10% Pharma Swede, Egypt); Nitroxynil (Dovix 25%, Arabcomed, Egypt); Rafoxanide (Flukanil 7.5%, Pharma Swede, Egypt) were purchased from veterinary drug stores. The effective concentrations of each flukicide selected based on findings obtained from our previous study . Albendazole 10% was dissolved in DMSO 1% at rates of 40 and 400 µg/ml in Petri dishes. Triclabendazole 10%, Nitroxynil 25% and Rafoxanide 7.5% were separately dissolved in DMSO 1% at rates of 50 and 100 µg/ml for each drug in Petri dishes. Five active flukes of the same size were gently added to each dish. Three replicates were evaluated for each concentration per flukicide. Dishes were incubated for 3 h at 37 °C. In the control group, flukes were incubated for 3 h at 37 °C DMSO 1% dissolved in saline. During the incubation, movement of all flukes in the Petri dishes was recorded. Three hours post, flukes were collected and washed again using normal saline 0.9% to remove remnants of the used drugs, then stored in 70% ethanol and they underwent scanning electron microscopy.
2.3 Parasitological parameters
Motility of the treated worms was macroscopically and microscopically observed at intervals of 5, 15, and 30 min throughout 3 h post-treatment. Moreover, eggs which deposited in each dish were counted microscopically to estimate the fecundity of the treated flukes.
2.4 Scanning electron microscopy (SEM) of the treated flukes
Flukes were fixed with 4% (v/v) gluteraldhyde in PBS buffer (pH 7.4) for 24 h at room temperature. Washing, dehydration and fixation of the samples were conducted . Examination of the prepared slides using high resolution SEM was done in Electron Microscope Unit, Faculty of Science, Beni-Suef University.
2.5 Statistical analysis
SPSS computer program v.22 (IBM, Armonk, NY, USA) was used for data analysis. Egg deposition per treatment was expressed as mean ± stander error (SE). Moreover, percent decrease in the mean number of egg deposition was calculated from the equation: mean of egg deposition of control – mean of egg deposition in treated group / mean of egg deposition of control × 100. Motility of the flukes was categorized into clear macroscopic (+ + +), moderate (+ +), mild ( +), and paralysis (–). P value less than 0.05 was considered significant.
3.1 Effect of flukicides on the motility of the treated worms
In the control untreated groups, Fasciola gigantica worms had a clear macroscopic movement (+ + +) throughout the first hour of the in vitro application. In the second hour, the movement was moderate (+ +). In the third hour, the movement reduced and scored as mild ( +). In nitroxynil-treated groups, mild movement of the worms was observed at the first 5 min post application. The macroscopic and microscopic movement disappeared after 15 min (–). Meanwhile, in rafoxanide-treated groups, the clear macroscopic movement was detected during the first 5–15 min post application. Moderate movement was observed at 15–30 min post-treatment with rafoxanide. Macroscopic and microscopic motility disappeared after 75 min of rafoxanide treatment. In albendazole-treated groups, a clear macroscopic movement of the worms was observed till 45 and 30 min at 40 and 400 µg/ml, respectively. Mild movement of the worms was observed at 90–160 min post-treatment. Macroscopic and microscopic motility disappeared after the third hour of the albendazole treatment. Similarly, in triclabendazole-treated group, flukes had a clear macroscopic movement till 45 and 30 min at 50 and 100 µg/ml, respectively. Mild macroscopic movement of the worms was observed at 75–120 min post-treatment. Macroscopic and microscopic motility disappeared after 160 min of treatment (Table 1).
3.2 Effect of flukicides on the fecundity of the treated worms
The mean of deposited eggs was significantly reduced (P ≤ 0.05) in all groups except in the group treated with albendazole 40 µg/ml compared to the control untreated worms. In albendazole-treated groups, the egg reduction was 43% and 75% at concentrations of 40 and 400 µg/ml, respectively. Meanwhile, in triclabendazole-treated flukes, the egg deposition was significantly reduced (p ≤ 0.05) to 76.6% and 88.3% on using concentrations of 50 µg/ml and 100 µg/ml, respectively. Regarding rafoxanide application, the use of 50 µg/ml and 100 µg/ml revealed a significant (P ≤ 0.05) reduction of the egg deposition to 70% and 85%, respectively. In nitroxynil-treated groups, the use of concentrations of 50 µg/ml and 100 µg/ml revealed a significant (P ≤ 0.05) reduction of the egg deposition to 88.3% and 95%, respectively (Table 2).
3.3 Scanning electron microscopy (SEM)
The untreated flukes showed a normal tegument with intact spines on both the dorsal and ventral surfaces. No damage was observed on the oral and ventral suckers. Dimensions of the ventral sucker ranged from 238 to 318 µm. The thickness of the tegument ranged from 248 to 297 µm. Dimensions of the spines were 33–40 µm (Fig. 1).
Meanwhile, in nitroxynil-treated flukes, the tegument elucidated severe furrowing and severe destruction in the spines particularly on middle and the tail of both surfaces. Thickness of the cuticle ranged from 302 to 484 µm. Dimensions of the ventral sucker ranged from 355 to 462 (Fig. 2).
In rafoxanide-treated flukes, the tegument had moderate furrowing and destruction of spines on the anterior, middle, and the tail of both surfaces. Thickness of the cuticle ranged from 328 to 498 µm. Dimensions of ventral sucker were 350–470 µm (Fig. 3).
In triclabendazole-treated flukes, the tegument showed swelling and mild furrowing. Spines were moderately damaged dorsally and mildly damaged on the ventral surface. Thickness of the cuticle ranged from 258 to 270. µm. Dimensions of the ventral sucker were 243–250 (Fig. 4).
In albendazole-treated flukes, the tegument revealed severe furrowing. Spines were sloughed dorsally and damaged on the ventral aspect. At a concentration of 400 mg/ml, the tegument was detached in some areas leaving the basal lamina exposed. Thickness of the cuticle ranged from 250 to 290 µm. Dimensions of ventral sucker were 250–260 (Fig. 5).
In the current study, the activity of the commercially used flukicides against Fasciola species in Egypt was investigated. Interestingly, findings of the used anthelmintics were recorded within a short time, 3 h. Moreover, worms were incubated in normal saline with no specific media. Thus, the present protocol is simple and could be conducted easily to estimate the preliminary screening of flukicide susceptibility prior to the field application. Nitroxynil induced the most potent flukicide effect compared with rafoxanide, triclabendazole and albendazole treatments. Nitroxynil-treated flukes showed a complete paralysis within 15 min post-treatment. Similarly, nitroxynil caused spastic paralysis and uncoupler of oxidative phosphorylation of the treated worms . Nitroxynil disrupt the oxidative phosphorylation process and prevent ATP formation inside flukes, thus, it suppresses their movement . Moreover, a sluggish movement of Fasciola species worms treated with nitroxynil was recorded . Currently, the egg deposition was significantly reduced in vitro at a rate of 88.3–95% based on nitroxynil application. The most potential flukicidal activity of nitroxynil was recorded in vivo previously. Nitroxynil efficacy was 99.1% against F. hepatica infecting cattle . Furthermore, in F. hepatica-naturally infected sheep flock in the west of Ireland, nitroxynil showed 100% reduction in the egg deposition . Moreover, nitroxynil was fully effective against triclabendazole-resistant flukes . Besides, in cattle infected with F. gigantica in Tanzania, the fecal egg reduction test was 100% after nitroxynil treatment . The egg reduction was significantly higher in nitroxynil-treated cattle compared with triclabendazole . In addition, nitroxynil was the most potent flukicide compared with clorsulon, closentel and triclabendazole in Mexico . In the present work, SEM findings of nitroxynil coincided with the flukicidal effect. There was severe furrowing in the tegument together with severe destruction in the spines particularly on the middle and the tail of both surfaces. The potency of nitroxynil to disrupt Fasciola species spines was recorded . Causes of spines disruption are unknown, but it might be that the destruction facilitates the entrance of the drug inside flukes [28, 39].
In vivo application showed that flukes collected from nitroxynil-treated rats were less active and their surface was swelled after 48 h, meanwhile, they showed little or no movement 72 h post-treatment . In the authors’ opinion, the action of nitroxynil was faster than the later study, because of the in vitro direct contact of the drug with the flukes and the high concentrations used. On the other hand, in vivo application requires a long time for the drug to be in a contact with the worms. Currently, nitroxynil had a potent and rapid flukicidal effect against F. gigantica adult worms.
Rafoxanide showed a less flukicidal effect. Paralysis of the treated flukes was recorded 75 min post application. Rafoxanide is a flukicide that causes depletion of glycogen, glucose-6-phosphate and ATP in mature flukes . Salicylanilides hinder energy metabolism through uncoupling oxidative phosphorylation in the worm . Salicylanilide flukicides: rafoxanide, closantel and oxyclozanide cause a quick paralysis in the flukes. For instance, closantel increased the muscle tone of F. hepatica followed by spastic paralysis within 2 h . The egg deposition was reduced to 70–85% in rafoxanide-treated groups. Similarly, the efficacy of rafoxanide against F. hepatica in naturally infected sheep was 86–88% based on the used concentration . Moreover, the efficacy of rafoxanide against F. hepatica in cattle was 90.1% . Furthermore, the egg reduction of F. hepatica-infected cattle and treated with rafoxanide was 68.2% . In addition, albendazole and rafoxanide showed a fecal egg count reduction of 75–80.58% during 7–84 days post-treatment, respectively . Meanwhile, the efficacy of rafoxanide against F. gigantica infected sheep was 98.78% . In the current investigation, SEM findings revealed a moderate furrowing of the tegument, a thickening in the cuticle as well as destruction of spines on the anterior, middle, and the tail of both surfaces. These findings agreed with those reported by Skuce and Fairweather  who recorded that salicylanilide flukicide (closantel) caused sloughing of F. hepatica tegument post 24 h in vivo using SEM. Therefore, rafoxanide induced a flukicidal effect less than that induced by nitroxynil. Paralysis of the worms was observed but it was later than that caused by nitroxynil.
In triclabendazole-treated flukes, the motility of the worms was observed till 160 min post-treatment. Moreover, the tegument showed a moderate damage, swelling and mild furrowing. Similarly, F. hepatica worms showed normal motility 48 h post-treatment and little morphological changes, after in vivo triclabendazole treatment, were observed . Moreover, 24 h post in vitro treatment with triclabendazole (TCBZ) and its sulfoxide (TCBZ–SO) and sulfone (TCBZ–SO2) metabolites, flukes were actively motile and they had swelling and blebbing of the tegument [30, 46]. In the authors’ opinion, the used concentrations of triclabendazole 50–100 µg/ml were higher than of the previous studies, thus, it induced more tegumental alterations. Triclabendazole reduced the egg deposition to 76.6–88.3%. Triclabendazole resistance was detected in Australia . Such flukicide failed to treat sheep infected with F. hepatica in Northern Ireland . Furthermore, F. hepatica was resistant to triclabendazole for the first time in Chile . On the contrary, findings of the egg hatching assay of a previous work cleared an early embryonic lysis and stopped hatching of F. gigantica eggs at various concentrations of triclabendazole . Notably, it was expecting that triclabendazole would be the most potent evaluated flukicide, but it seems that the resistance of such product has emerged in Egypt.
Albendazole had the least flukicidal effect; motility disappeared after the third hour of the treatment. Reduction of egg deposition was 43–75%. Although albendazole induced the most potent tegumental changes, flukes were active and deposited egg masses at the concentration of 400 µg/ml. Conversely, albendazole sulfoxide metabolite 10 µg/ml induced localized blebbing 24 h post-treatment . In the authors’ opinion, the used albendazole concentrations were high enough to induce clear tegumental damage but it could not induce a potent flukicidal effect. In our previous literature, albendazole showed 73.7% efficacy against Fasciola species in naturally infected cattle . In addition, albendazole achieved 79.17% efficacy against fascioliasis in water buffaloes in the Philippines . Moreover, a lower efficacy of albendazole (67%) against F. hepatica in sheep was recorded in Sweden . Furthermore, albendazole showed 77–81.8% efficacy in cattle naturally infected with F. hepatica in Slovakia, and the ovicidal activity was 65.40% . Thus, albendazole could not be considered a potent flukicide against fascioliasis among infected livestock.
Screening high concentrations of flukicides against F. gigantica added useful data that assist to select the suitable drug. Nitroxynil was the most potent flukicide, and the tegument of the treated worms showed severe damage. A lower efficacy of triclabendazole was documented for the first time in Egypt. Albendazole could not be recommended against fascioliasis. Further in vivo study will be conducted for a proper understanding the efficacy and or resistance of the commonly used flukicides against liver flukes in cattle and buffaloes in Egypt.
Availability of data and materials
Data and materials are available.
Scanning electron microscopy
McManus DP, Dalton JP (2006) Vaccines against the zoonotic trematodes Schistosoma japonicum, Fasciola hepatica and Fasciola gigantica. Parasitology 133:43–61. https://doi.org/10.1017/S0031182006001806
Rioux MC, Carmona C, Acosta D, Ward B, Ndao M, Gibbs BF, Bennett HP, Rioux MC, Carmona C, Acosta D, Ward B, Ndao M, Gibbs BF, Bennett HP, Spithill TW (2008) Discovery and validation of serum biomarkers expressed over the first twelve weeks of Fasciola hepatica infection in sheep. Int J Parasitol 38(1):123–136. https://doi.org/10.1016/j.ijpara.2007.07.017
El-Shazly AM, Nabih N, Salem DA, Mohamed MZ (2012) Snail populations in Dakahlia governorate Egypt with special reference to lymnaeids. Egypt J Biol 14:45–49
Kaplan RM (2001) Fasciola hepatica: a review of the economic impact in cattle and considerations for control. Vet Ther 2(1):40–50
Yusuf M, Ibrahim N, Tafese W, Deneke Y (2016) Prevalence of bovine fasciolosis in municipal abattoir of Haramaya. Ethiopia Food Sci Qual Manag 48:38–43
Dar Y, Amer S, Mercier A, Courtioux B, Dreyfuss G (2012) Molecular identification of Fasciola spp. (Digenea: Fasciolidae) in Egypt. Parasite 19(2):177–182. https://doi.org/10.1051/parasite/2012192177
Bazh EK, Beder NA, Ayoub M, Sadek K (2012) Fasciola infection among cattle and buffaloes at Behera Governorate. Egypt Zagazig Vet J 40:125–136
Haseeb AN, el-Shazly AM, Arafa MA, Morsy AT, (2002) A review on fascioliasis in Egypt. J Egypt Soc Parasitol 32(1):317–354
Silvestre A, Cabaret J (2002) Mutation in position 167 of isotype 1 beta-tubulin gene of Trichostrongylid nematodes: role in benzimidazole resistance ? Mol Biochem Parasitol 120(2):297–300. https://doi.org/10.1016/s0166-6851(01)00455-8
Lacey E (1990) Mode of action of benzimidazoles. Parasitol Today 6(4):112–115. https://doi.org/10.1016/0169-4758(90)90227-u
Coles GC (1994) Parasite control in sheep. In Pract 16:309–318
Horton J (2000) Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology 121:113–132. https://doi.org/10.1017/s0031182000007290
Reuter S, Jensen B, Buttenschoen K, Kratzer W, Kern P (2000) Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature. J Antimicrob Chemother 46(3):451–456. https://doi.org/10.1093/jac/46.3.451
Keiser J, Engels D, Büscher G, Utzinger J (2005) Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Investig Drugs 14(12):1513–1526. https://doi.org/10.1517/13543718.104.22.1683
Gandhi P, Schmitt EK, Chen CW, Samantray S, Venishetty VK, Hughes D (2019) Triclabendazole in the treatment of human fascioliasis: a review. Trans R Soc Trop Med Hyg 113(12):797–804. https://doi.org/10.1093/trstmh/trz093
Fairweather I (2005) Triclabendazole: new skills to unravel an old (ish) enigma. J Helminthol 79(3):227–234. https://doi.org/10.1079/joh2005298
Swan GE (1999) The pharmacology of halogenated salicylanilides and their anthelmintic use in animals. J S Afr Vet Assoc 70(2):61–70
Rapic D, Dzakula N, Sakar D, Richards RJ (1988) Comparative efficacy of triclabendazole, nitroxynil and rafoxanide against immature and mature Fasciola hepatica in naturally infected cattle. Vet Rec 122(3):59–62. https://doi.org/10.1136/vr.122.3.59
Richards RJ, Bowen FL, Essenwein F, Steiger RF, Büscher G (1990) The efficacy of triclabendazole and other anthelmintics against Fasciola hepatica in controlled studies in cattle. Vet Rec 126(9):213–216
Fairweather I, Boray JC (1999) Fasciolicides: efficacy, actions, resistance and its management. Vet J 158(2):81–112. https://doi.org/10.1053/tvjl.1999.0377
Wolstenholme AJ, Fairweather I, Prichard R, von Samson-Himmelstjerna G, Sangster NC (2004) Drug resistance in veterinary helminths. Trends Parasitol 20(10):469–476. https://doi.org/10.1016/j.pt.2004.07.010
Arafa WM, Holman PJ, Craig TM (2017) Genotypic and phenotypic evaluation for benzimidazole resistance or susceptibility in Haemonchus contortus isolates. Parasitol Res 116(2):797–807. https://doi.org/10.1007/s00436-016-5357-y
- Boray JC. Drug resistance in Fasciola hepatica. InResistance of parasites to antiparasitic drugs: Round Table Conference, ICOPA VII Paris 1990. 1990 (pp 51-60). Merck & Co. Inc
Novobilský A, Averpil HB, Höglund J (2012) The field evaluation of albendazole and triclabendazole efficacy against Fasciola hepatica by coproantigen ELISA in naturally infected sheep. Vet Parasitol 190(1–2):272–276. https://doi.org/10.1016/j.vetpar.2012.06.022
Overend DJ, Bowen FL (1995) Resistance of Fasciola hepatica to triclabendazole. Aust Vet J 72(7):275–276. https://doi.org/10.1111/j.1751-0813.1995.tb03546.x
Robles-Pérez D, Martínez-Pérez JM, Rojo-Vázquez FA, Martínez-Valladares M (2014) Development of an egg hatch assay for the detection of anthelmintic resistance to albendazole in Fasciola hepatica isolated from sheep. Vet Parasitol 203(1–2):217–221. https://doi.org/10.1016/j.vetpar.2013.11.020
Arafa WM, Shokeir KM, Khateib AM (2015) Comparing an in vivo egg reduction test and in vitro egg hatching assay for different anthelmintics against Fasciola species, in cattle. Vet Parasitol 214(1–2):152–158. https://doi.org/10.1016/j.vetpar.2015.09.023
McKinstry B, Fairweather I, Brennan GP, Forbes AB (2003) Fasciola hepatica: tegumental surface alterations following treatment in vivo and in vitro with nitroxynil (Trodax). Parasitol Res 91(3):251–263. https://doi.org/10.1007/s00436-003-0930-6
Buchanan JF, Fairweather I, Brenna GP, Trudgett A, Hoey EM (2003) Fasciola hepatica: surface and internal tegumental changes induced by treatment in vitro with the sulphoxide metabolite of albendazole ('Valbazen’). Parasitology 126(2):141–153. https://doi.org/10.1017/s0031182002002664
Halferty L, Brennan GP, Trudgett A, Hoey L, Fairweather I (2009) Relative activity of triclabendazole metabolites against the liver fluke. Fasciola Hepatica Vet Parasitol 159(2):126–138. https://doi.org/10.1016/j.vetpar.2008.10.007
Ashrafi K, Valero MA, Panova M, Periago MV, Massoud J, Mas-Coma S (2006) Phenotypic analysis of adults of Fasciola hepatica, Fasciola gigantica and intermediate forms from the endemic region of Gilan. Iran Parasitol Int 55(4):249–260. https://doi.org/10.1016/j.parint.2006.06.003
Keiser J, Shu-Hua X, Tanner M, Utzinger J (2006) Artesunate and artemether are effective fasciolicides in the rat model and in vitro. J Antimicrob Chemother 57(6):1139–1145. https://doi.org/10.1093/jac/dkl125
Omran EK, Ahmad NS (2015) Effect of nitroxynil (fasciolid) on adult Fasciola gigantica and Fasciola hepatica in infected cows. Parasitol United J 8(2):107–114. https://doi.org/10.4103/1687-7942.175008
Mooney L, Good B, Hanrahan JP, Mulcahy G, de Waal T (2009) The comparative efficacy of four anthelmintics against a natural acquired Fasciola hepatica infection in hill sheep flock in the west of Ireland. Vet Parasitol 164(2–4):201–205. https://doi.org/10.1016/j.vetpar.2009.05.017
Hanna RE, McMahon C, Ellison S, Edgar HW, Kajugu PE, Gordon A, Irwin D, Barley JP, Malone FE, Brennan GP, Fairweather I (2015) Fasciola hepatica: a comparative survey of adult fluke resistance to triclabendazole, nitroxynil and closantel on selected upland and lowland sheep farms in Northern Ireland using faecal egg counting, coproantigen ELISA testing and fluke histology. Vet Parasitol 207(1–2):34–43. https://doi.org/10.1016/j.vetpar.2014.11.016
Nzalawahe J, Hannah R, Kassuku AA, Stothard JR, Coles G, Eisler MC (2018) Evaluating the effectiveness of trematocides against Fasciola gigantica and amphistomes infections in cattle, using faecal egg count reduction tests in Iringa Rural and Arumeru Districts. Tanzania Parasit Vectors 11(1):384. https://doi.org/10.1186/s13071-018-2965-7
Romero J, Villaguala C, Quiroz F, Landaeta-Aqueveque C, Alfaro G, Pérez R (2019) Flukicide efficacy against Fasciola hepatica of triclabendazole and nitroxynil in cattle of the central valley of Chile. Rev Bras Parasitol Vet 28(1):164–167. https://doi.org/10.1590/S1984-296120180089
Ico-Gómez R, González-Garduño R, Ortiz-Pérez D, Mosqueda-Gualito JJ, Flores-Santiago E, Sosa-Pérez G, Salazar-Tapia AA (2021) Assessment of anthelmintic effectiveness to control Fasciola hepatica and paramphistome mixed infection in cattle in the humid tropics of Mexico. Parasitology 148(12):1458–1466. https://doi.org/10.1017/S0031182021001153
McConville M, Brennan GP, McCoy M, Castillo R, Hernandez-Campos A, Ibarra F, Fairweather I (2006) Adult triclabendazole-resistant Fasciola hepatica: surface and subsurface tegumental responses to in vitro treatment with the sulphoxide metabolite of the experimental fasciolicide compound alpha. Parasitology 133(2):195–208. https://doi.org/10.1017/S0031182006000114
McKinstry B, Brennan GP, Halferty L, Forbes AB, Fairweather I (2007) Ultrastructural changes induced in the tegument and gut of Fasciola hepatica following in vivo and in vitro drug treatment with nitroxynil (Trodax). Parasitol Res 101(4):929–941. https://doi.org/10.1007/s00436-007-0564-1
Skuce PJ, Fairweather I (1990) The effect of the hydrogen ionophore closantel upon the pharmacology and ultrastructure of the adult liver fluke Fasciola hepatica. Parasitol Res 76(3):241–250. https://doi.org/10.1007/BF00930821
Mohammed-Ali NA, Bogan JA (1987) The pharmacodynamics of the flukicidal salicylanilides, rafoxanide, closantel and oxyclosanide. J Vet Pharmacol Ther 10(2):127–133. https://doi.org/10.1111/j.1365-2885.1987.tb00089.x
Elitok B, Elitok OM, Kabu M (2006) Field trial on comparative efficacy of four fasciolicides against natural liver fluke infection in cattle. Vet Parasitol 135(3–4):279–285. https://doi.org/10.1016/j.vetpar.2005.10.008
Shokier KM, Aboelhadid SM, Waleed MA (2013) Efficacy of five anthelmintics against a natural Fasciola species infection in cattle. Beni-Suef Univ J Basic Appl Sci 2(1):41–45
Kadhim JK (1975) The comparative efficacy of diamphenethide and rafoxanide against Fasciola gigantica in sheep. Tropenmed Parasitol 26(2):201–204
Halferty L, Brennan GP, Hanna RE, Edgar HW, Meaney MM, McConville M, Trudgett A, Hoey L, Fairweather I (2008) Tegumental surface changes in juvenile Fasciola hepatica in response to treatment in vivo with triclabendazole. Vet Parasitol 155(1–2):49–58. https://doi.org/10.1016/j.vetpar.2008.04.011
Venturina VM, Alejandro MA, Baltazar CP, Abes NS, Mingala CN (2015) Evidence of Fasciola spp. resistance to albendazole, triclabendazole and bromofenofos in water buffaloes (Bubalus bubalis). Ann Parasitol 61(4):283–289
Novobilský A, Amaya Solis N, Skarin M, Höglund J (2016) Assessment of flukicide efficacy against Fasciola hepatica in sheep in Sweden in the absence of a standardised test. Int J Parasitol Drugs Drug Resist 6(3):141–147. https://doi.org/10.1016/j.ijpddr.2016.06.004
Babják M, Königová A, Burcáková Ľ, Komáromyová M, Dolinská MU, Várady M (2021) Assessing the efficacy of albendazole against Fasciola hepatica in naturally infected cattle by in vivo and in vitro methods. Vet Sci 8(11):249. https://doi.org/10.3390/vetsci8110249
Authors kindly acknowledge all veterinarians and authorities who facilitated specimens collection.
No funding sources.
Ethics approvals and consent to participate
Ethics approvals and consent to participate not applicable, as no specimens were taken from condemned parts in abattoirs with any experiments done for animals or humans.
Consent for publication
All authors give their consent for the publication of this article.
Authors declare that there is no competing of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Abdel‑Fatah, O.R., Arafa, W.M., Wahba, A.A. et al. Tegumental alterations and resistance of Fasciola gigantica adult worms exposed to flukicides in Egypt. Beni-Suef Univ J Basic Appl Sci 11, 106 (2022). https://doi.org/10.1186/s43088-022-00287-z
- Fasciola gigantica
- Egg reduction
- Cuticular alterations